AzTrials
AzTrials

Myocardial InfarctionNCT05972070

Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence

An observational study of Myocardial Infarction and Percutaneous Transluminal Coronary Angioplasty, run by ROM Technologies, INC at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of this study is to evaluate feasibility, efficacy, and adherence of home-based cardiac rehabilitation with the integration of telemedicine. Several components will be assessed such as quality-of-life, nutritional counseling, maximum metabolic activity (MET's), diabetic management, tobacco cessation, lipid… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
ROMTech Portable Connect
Type of treatment
Medical device
How many people
500 participants
Where
1 siteUnited States
Study dates
1 Jun 2023to 31 Dec 2025
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients who have undergone surgical or percutaneous coronary revascularization due to atherosclerotic coronary artery disease.

Who may be able to join

  • Over the age of 18
  • NYHA Functional Class I, II,
  • Recent (within 60 days) status post coronary artery revascularization for atherosclerotic coronary artery disease (coronary artery bypass grafting or percutaneous coronary revascularization with stent implantation)
  • Candidate for traditional center-based cardiac rehabilitation

Who cannot join

  • Under the age of 18
  • Adults lacking capacity to consent.
  • NYHA Functional Class III, IV
  • Acute coronary syndrome
  • Systolic heart failure (LV EF <40%)
  • Status post cardiac surgery for structural heart disease or heart transplant
Show all 9Show fewer
  • Percutaneous coronary angioplasty
  • Adults lacking capacity to consent.
  • Pregnant women

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

LaToya T. King contact

2035184735

Latoya.King@romtech.com

United States1 site, 1 recruiting
  • ROMTech

    Brookfield, Connecticut, 06804

    LaToya T King, 203-518-4735, Latoya.King@romtech.com

    John Stulak, MD

    Recruiting

Other trials in United States

About this study

The aim of this study is to evaluate feasibility, efficacy, and adherence of home-based cardiac rehabilitation with the integration of telemedicine. Several components will be assessed such as quality-of-life, nutritional counseling, maximum metabolic activity (MET's), diabetic management, tobacco cessation, lipid, blood pressure, and psychosocial management. These tasks will be accomplished through concurrent conversations between patients and their therapist's utilizing telemedicine with observed exercise training.

Read the detailed description

The focus of this study is to determine the feasibility, efficacy, and adherence of home-based cardiac rehabilitation with the integration of telemedicine. The study consists of an initial review, rehabilitation sessions, nutrition consultation, and risk stratification. Once the patient is cleared for the rehabilitation program, they will be assigned a cardiac rehab specialist and begin the 36 rehabilitation sessions. The sessions include pre-session questions, surveys, pre-, during, and post vitals, exercise protocol, and off-the-device exercises.

Being tested
ROMTech Portable Connect
Keywords
Cardiac rehabilitation, Home based cardiac rehabilitation, Telemedicine and Home-Based Cardiac Rehabilitation
Medical subject headings
Myocardial Infarction, Angina, Stable, Heart Failure, Heart Valve Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ROMTech Portable ConnectDevice

    Also called ROMTech PC, ROMTech PortableConnect Rehab System

    The ROMTech PortableConnect Rehab System is a continuous rehabilitative exercise therapy device that uses assisted movement to measure, evaluate, exercise, re-educate and strengthen muscles, and to increase joint range of motion.

Study groups in NCT05972070
Study groupRoleWhat they receive
Cardiac patientsAdult patients who have undergone surgical or percutaneous coronary revascularization due to atherosclerotic coronary artery disease.
Receives: Device: ROMTech Portable Connect

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Session attended

    Measure the number of sessions attended to determine the ease of patients to utilize home-based cardiac rehab integrated with telemedicine (non-inferiority to historical controls)

    Measured: 12 weeks (End of treatment)

  2. Sessions completed

    Measure the number of sessions completed to determine compliance of patients to utilize home-based cardiac rehab integrated with telemedicine

    Measured: 12 weeks(End of treatment)

  3. Duke Activity Status Index (DASI)

    Estimate of functional capacity

    Measured: Baseline, 12 weeks (End of Treatment)

  4. Patient Health Questionnaire(PHQ)

    Quality of Life assessment

    Measured: Baseline, 12 weeks (End of Treatment)

  5. Short Physical Performance Battery

    Lower extremity functional assessment

    Measured: Baseline, 12 weeks (End of Treatment)

  6. Short Form-36

    Quality of Life assessment

    Measured: Baseline, 12 weeks (End of Treatment)

Secondary outcomes (1)
  1. Laboratory assessment

    To determine if there is an improvement in low density lipoprotein, triglycerides,

    Measured: Baseline, 12 weeks (End of Treatment)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Aug 2023
  2. Study start1 Jun 2023
  3. Primary completion31 Oct 2025 (estimated)
  4. Study completion31 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05972070
Sponsor's protocol ID
ROMTherapy_HBCR_1001
Status last verified
Jul 2025
First submitted
3 Jul 2023
Last updated
24 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Myocardial Infarction and Percutaneous Transluminal Coronary Angioplasty, run by ROM Technologies, INC at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact LaToya T. King (2035184735, Latoya.King@romtech.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Session attended (time frame: 12 weeks (End of treatment)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2025; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in